One - Stop Research Support for CAR - NK Therapy

CARNK cell therapies are novel therapeutic options developed with the aim to overcome some limitations of CART cell therapies, such as therapy induced side effects. CARNK cells exhibit higher cytolytic activity than memory T cells and untransduced NK cells; thus, being more effective in killing tumor cells. Currently, over 800 CART and 28 CARNK cell clinical trials are being conducted worldwide.

As a global leading supplier of bioreagents and CRO services for the biopharmaceutical field, Sino

Biological provides comprehensive solutions for CARNK cell therapy development. Our reagents and services can support our customers from early target discovery to the preclinical phase of research and

development.